Want to take quizzes and track your credits?
In the 2014 Ebola outbreak, close to 30 000 individuals developed Ebola viral disease (EVD), and numerous therapies were tested against this virus, including chloroquine, hydroxychloroquine, favipiravir, brincidofovir, monoclonal antibodies, antisense RNA, and convalescent plasma, among many others. With such a large number of therapeutic interventions given to affected patients, the goal was to determine which was efficacious against Ebola. Ultimately, none proved to be efficacious or safe.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Andre C. Kalil, MD, MPH, Department of Internal Medicine, University of Nebraska Medical Center, 95400 Nebraska Medical Center, Omaha, NE 68135 (firstname.lastname@example.org).
Published Online: March 24, 2020. doi:10.1001/jama.2020.4742
Conflict of Interest Disclosures: None reported.
You currently have no searches saved.
You currently have no courses saved.